FDA approves ribociclib with an aromatase inhibitor and ribociclib …
WEB4 days ago · Efficacy of ribociclib with a non-steroidal aromatase inhibitor (NSAI) was evaluated in NATALEE (NCT03701334), a randomized, open-label, multicenter trial in 5101 adults with HR-positive, HER2 ...
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
WEB3 days ago · The FDA has approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor (AI) for the treatment of patients with hormone receptor–positive, HER2-negative stage II and III early breast ...
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
WEB1 day ago · Ribociclib dosing for the adjuvant indication is lower than for metastatic disease, but patients are on the same schedule — two 200 mg tablets once daily for 21 days followed by 7 days off in 28 ...
Kisqali Approved for HR+, HER2- Early Breast Cancer
WEB2 days ago · At 36 months, the iDFS rate was 90.7% in the ribociclib arm and 87.6% in the control arm (hazard ratio [HR], 0.749; 95% CI, 0.628, 0.892). Overall survival data were immature at the final iDFS ...
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast …
WEB4 days ago · The FDA has approved ribociclib (Kisqali) plus an aromatase inhibitor as adjuvant treatment for patients with hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer at high risk of recurrence, according to a press release from Novartis. 1. The dosing information included a once daily oral dose of ribociclib at 400 ...
Ribociclib Combo Yields Extended iDFS Benefit in HR+/HER2– …
WEB5 days ago · Combining ribociclib (Kisqali) with nonsteroidal aromatase inhibitor (NSAI) therapy demonstrated sustained improvements in invasive disease-free survival (iDFS) and distant disease-free survival (DDFS) vs NSAI alone among patients with hormone receptor (HR)–positive, HER2-negative early breast cancer, according to 4-year landmark analysis data from the phase 3 NATALEE trial (NCT03701334 ...
Kisqali Approved for HR-Positive, HER2-Negative Early Breast Cancer
WEB2 days ago · Findings showed treatment with ribociclib plus endocrine therapy significantly reduced the risk of disease recurrence by 25.1% (hazard ratio, 0.749 ... News release. Novartis. September 17, 2024.
Ribociclib Improves Survival in Advanced Breast Cancer
WEBOct 6, 2021 · Women with metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their initial treatment lived approximately 1 year longer overall than women treated with letrozole only, updated results from the MONALEESA-2 …
Overall Survival with Ribociclib plus Letrozole in Advanced Breast ...
WEBMar 9, 2022 · First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast...
Ribociclib plus Endocrine Therapy in Early Breast Cancer
WEBMar 20, 2024 · The 3-year regimen of ribociclib at a 400-mg starting dose plus an NSAI was not associated with any new safety signals. Conclusions. Ribociclib plus an NSAI significantly improved invasive...